Fetal fraction of free-DNA: clinical-diagnostic parallels
https://doi.org/10.52420/2071-5943-2021-20-1-30-35
Abstract
Introduction. Since 2011, a technology such as a non-invasive prenatal test (NIPT) has been used in the world i order o identify pregnant women at a high risk of giving birth to a child with chromosomal aneuploidy (CA). An important indicator of the test's effectiveness is the fetal fraction (FF), since its low level does not allow to give a reliable result to a patient.
Aims: to determine the factors that can affect the level of FF during NIPT.
Materials and methods. A retrospective comparative covenant study was carried out. The study included 288 patients who underwent NIPT in 2015-2018 after the standard complex of prenatal diagnosis (t 12-18 weeks of pregnancy). We assessed the correlation of the FF level with various clinical and anamnestic parameters and with indicators of biochemical screening for the first trimester (PAPP-A and β-ХГЧ). A comparison was made in terms of the FF level during pregnancy with a favorable and unfavorable outcome.
Results. The average FF level in patient where CA was detected in the fetus was 9.01 (5.4-11)%, in the absence of CA — 9.7 (6.5-11.95)%, the difference are not statistically significant (p = 0.37). In patients with a physiological course of pregnancy, this indicator was 10.07 (6.6-12.57)%, and in patients with a complicated course of pregnancy, it was significantly lower — 8.11 (5.35-11.29)% (p = 0.02). We also analyzed the presence of a correlation between the level of FF and fetal weight at term, but no statistically significant correlation was found (r=0.13). There is a statistically significant inverse relationship between the FF level d the age of the pregnant woman, the patient's weight and body mass index, the number of pregnancies in the anamnesis, as well as a direct relationship between the FF and the β-hCG level (in MoM).
Conclusions. FF is an important parameter of NIPT. A sufficient level of FF not only indicates a high reliability of the result obtained during NIPT, but also increases the chances of a favorable pregnancy outcome. The level of FF can be influenced by a number of clinical and anamnestic characteristics of the patient (weight body mass index, age, obstetric history). Studies aimed at determining the level of FF in various physiological and pathological conditions during pregnancy seem promising and thanks to them, it is possible that new models for predicting pregnancy complications will subsequently be proposed.
About the Authors
E. V. Kudryavtseva
Ural State Medical University
Russian Federation
Russian Federation
Elena V. Kudryavtseva, PhD, associate professor
Ekaterinburg
V. V. Kovalev
Ural State Medical University
Russian Federation
Russian Federation
Vladislav V. Kovalev, MD, PhD, Professor
Ekaterinburg
A. A. Dektyarev
Clinical Institute of Reproductive Medicine
Russian Federation
Russian Federation
Andrew A. Dektyarev
Ekaterinburg
References
1. Verma, I. C. ACMG 2016 Update on Noninvasive Prenatal Testing for Fetal Aneuploidy: Implications for India / I. C. Verma, R. Dua-Puri, S. J. Bijarnia-Mahay // Fetal Med. – 2017. – Vol. 4. – P. 1-6. – Doi: 10.1007/s40556-017-0116-4.
2. Non-invasive prenatal testing: a review of international implementation and challenges / Allyse M., Minear M.A., Berson E. [et al.] // Int J Womens Health. – 2015. – Vol. 16 (7). – Р. 113-26. – Doi: 10.2147/IJWH.S67124.
3. Неинвазивный пренатальный тест в России: популяционное исследование / Кудрявцева Е. В., Канивец И. В., Киевская Ю. К. [и др.] // Акушерство и гинекология. – 2019. – № 12. – С. 30-5. – Doi https://dx.doi.org/10.18565/aig.2019.12.30-35.
4. Taglauer, E. S. Review: cell-free fetal DNA in the maternal circulation as an indication of placentahealth and disease / E. S. Taglauer, L. Wilkins-Haug, D. W. Bianchi // Placenta. – 2014. – Vol. 35. – Р. S64-8. – Doi: 10.1016/j.placenta.2013.11.014.
5. Новые подходы к проведению пренатального скрининга хромосомной патологии: ДНК-скрининг по крови матери / Сухих Г. Т., Трофимов Д. Ю., Барков И. Ю. [и др.] // Акушерство и гинекология. – 2016. – № 8. – С. 72-78. – Doi: 10.18565/aig.2016.8.72-78.
6. Norton, M. E. Cell-free DNA Analysis for Noninvasive Examination of Trisomy / M. E. Norton, R. J. Wapner // N Engl J Med. – 2015. – Vol. 373 (26). – Р. 2582. – Doi: 10.1056/NEJMc1509344.
7. Sequencing of short cfDNA fragments in NIPT improves fetal fraction with higher maternal BMI and early gestational age / Qiao L., Zhang Q., Liang Y. et al. // Am J Transl Res. – 2019. – Vol. 11 (7). – Р. 4450-4459.
8. Dabi, Y. Low-molecular-weight heparin associated with reduced fetal fraction and subsequent false-negative cell-free DNA test result for trisomy 21 / Y. Dabi, J. M. Costa, A. Benachi // Ultrasound Obstet Gynecol. – 2018. – Vol. 51, № 2. – P. 278.
9. The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction / W. Burn, N. Koelper, A. Barberio [et al.] // Prenat Diagn. – 2017. – Vol. 37, № 11. – P. 1125-1129.
10. Cell-free fetal DNA testing in singleton IVF conceptions / Lee T. J., Rolnik D. L., Menezes M. A. [et al.] // Hum Reprod. – 2018. – Vol. 33 (4). – Р. 572-578. – Doi: 10.1093/humrep/dey033.
11. Assotiation between fetal fraction on cell-free DNA testing and first trimester markers for preeclampsia / Rolnik D. L., da Silva Costa F., Lee T. J. [et al.] / Ultrasound Obstet Gynecol. – 2018. – Vol. 31 (8). – Р. 12-27. – Doi: https://doi.org/10.1002/uog.18993.
12. Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing / Krishna I., Badell M., Loucks T. L. [et al.] // Prenat Diagn. – 2016. – Vol. 36 (3). – Р. 210-5. – Doi: 10.1002/pd.4779.
13. Fetal cell-free DNA fraction in maternal plasma for the prediction of hyperten-sive disorders of pregnancy / Suzumori N., Sekizawa A., Ebara T. [et al.] // Eur J Obstet Gynecol Reprod Biol. – 2018. – Vol. 224. – Р. 165-169. – Doi: 10.1016/j.ejogrb.2018.03.048.
14. Trisomy 13 and the risk of gestatil hypertensive disorders: a population-based study / Dotters-Katz S. K., Humphrey W. M., Senz K. L. [et al.] // J Ma-tern Fetal Neonatal Med. – 2018. – Vol. 31 (15). – Р. 1951-1955. – Doi: 10.1080/14767058.2017.1332037.
15. Kinnings, S. L. Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing / S. L. Kinnings, J. A. Geis, E. Almasri // Prenat Diagn. – 2015. – Vol. 35 (8). – Р. 816-822. – Doi: https:// doi.org/10.1002/pd.4625.
16. ACOG commetee opinion № 640 : Cell-free DNA screening for fetal aneuploidy. – 2015. – https://pubmed.ncbi.nlm.nih.gov/26287791.
17. The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy popularion / Palomaki G. E., Kloza E. M., O’Brien B. M. [et al.] // Genetics in Medicine. – 2017. – Vol. 19 (7). – Р. 778–86. – Doi: 10.1038/gim.2016.194.
18. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes / Poon L. C., Musci T., Song K. [et al.] // Fetal Diagn Ther. – 2013. – Vol. 33 (4). – Р. 215-23. – Doi: 01159/000346806.
19. Di Renzo, G. C. The great obstetrical syndromes // J Matern Fetal Neonatal Med. – 2009. – Vol. 22 (8). – Р. 633-5. – Doi: 11080/14767050902866804.
20. Romero, R. Prenatal medicine: the child is the father of the man. 1996 // J Matern Fetal Neonatal Med. – 2009. – Vol. 22 (8). – Р. 636-9. – Doi: 10.1080/14767050902784171.
Review
For citations:
Kudryavtseva EV, Kovalev VV, Dektyarev AA. Fetal fraction of free-DNA: clinical-diagnostic parallels. Ural Medical Journal. 2021;20(1):30-35. (In Russ.) https://doi.org/10.52420/2071-5943-2021-20-1-30-35
Views:
472
Email this article 